Kidney cancer, also known as renal cell cancer, begins in the kidneys and is common among adults and children (many children develop a specific kind of kidney cancer called Wilms' tumor). Risk of developing kidney cancer increases with age, smoking, being male, obesity, hypertension, exposure to chemicals, von hippel-lindau disease, treatment for kidney failure, and family history. Kidney cancer is most commonly treated with surgery, cryoablation, radiofrequency ablation, drug therapy, radiation therapy, and targeted therapy. In metastatic renal cell cancer, the cancer has spread to other organs such as lymph nodes, the lungs, liver, bones, or the brain. An estimated 70% of patients will develop metastases throughout their disease. This is not a good prognosis as survival rates of 5 years is about 5-15%. Survival rates are improved if surgery to remove all visible disease is performed. Radiation and chemotherapy are not typically used in metastatic renal cell cancer, but may be used in various situations.
Metastatic Renal Cell Cancer Bioinformatics Tool
Laverne is a handy bioinformatics tool to help facilitate scientific exploration of related genes, diseases and pathways based on co-citations. Explore more on Metastatic Renal Cell Cancer below!
For more information on how to use Laverne, please read the How to Guide.
We have 2558 products for the study of Metastatic Renal Cell Cancer that can be applied to Western Blot, Immunocytochemistry/Immunofluorescence, Flow Cytometry, Immunohistochemistry, Chromatin Immunoprecipitation (ChIP) from our catalog of antibodies and ELISA kits.